The stock of ImmunityBio Inc (NASDAQ: IBRX) has decreased by -4.83 when compared to last closing price of 5.28. Despite this, the company has experienced a -18.56% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-30 that NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on June 30, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company.
Is It Worth Investing in ImmunityBio Inc (NASDAQ: IBRX) Right Now?
The 36-month beta value for IBRX is also noteworthy at 0.78. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for IBRX is 159.51M, and at present, short sellers hold a 32.34% of that float. The average trading volume of IBRX on November 04, 2024 was 4.67M shares.
IBRX’s Market Performance
IBRX stock saw an increase of -18.56% in the past week, with a monthly gain of 46.50% and a quarterly increase of 16.86%. The volatility ratio for the week is 13.38%, and the volatility levels for the last 30 days are 11.50% for ImmunityBio Inc (IBRX). The simple moving average for the past 20 days is 18.51% for IBRX’s stock, with a -2.94% simple moving average for the past 200 days.
Analysts’ Opinion of IBRX
Many brokerage firms have already submitted their reports for IBRX stocks, with Piper Sandler repeating the rating for IBRX by listing it as a “Neutral.” The predicted price for IBRX in the upcoming period, according to Piper Sandler is $4 based on the research report published on May 12, 2023 of the previous year 2023.
Jefferies, on the other hand, stated in their research note that they expect to see IBRX reach a price target of $8. The rating they have provided for IBRX stocks is “Buy” according to the report published on August 03rd, 2022.
IBRX Trading at 29.53% from the 50-Day Moving Average
After a stumble in the market that brought IBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.28% of loss for the given period.
Volatility was left at 11.50%, however, over the last 30 days, the volatility rate increased by 13.38%, as shares surge +43.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +17.53% upper at present.
During the last 5 trading sessions, IBRX fell by -19.04%, which changed the moving average for the period of 200-days by +38.75% in comparison to the 20-day moving average, which settled at $4.24. In addition, ImmunityBio Inc saw 0.10% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IBRX
Current profitability levels for the company are sitting at:
- -274.59 for the present operating margin
- -12.85 for the gross margin
The net margin for ImmunityBio Inc stands at -456.92. The total capital return value is set at -0.94.
Based on ImmunityBio Inc (IBRX), the company’s capital structure generated 3.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.43. The debt to equity ratio resting at -1.38. The interest coverage ratio of the stock is -74.86.
Currently, EBITDA for the company is -342.85 million with net debt to EBITDA at -2.48. When we switch over and look at the enterprise to sales, we see a ratio of 3369.5. The receivables turnover for the company is 0.63for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.91.
Conclusion
In summary, ImmunityBio Inc (IBRX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
